Schultz, Martin http://orcid.org/0000-0002-1259-645X
Rasmussen, Line J. H.
Kallemose, Thomas
Kjøller, Erik
Lind, Morten N.
Ravn, Lisbet
Lange, Theis
Køber, Lars
Rasmussen, Lars S.
Eugen-Olsen, Jesper
Iversen, Kasper
Article History
Received: 4 October 2018
Accepted: 26 March 2019
First Online: 11 April 2019
Ethics approval and consent to participate
: The Danish Data Protection Agency approved the TRIAGE III trial (HGH-2015-042, I-Suite no. 04087) as well as the Danish Patient Safety Authority (Ref.no. 3–3013-1744/1). The trial was presented to the Regional Ethics Committee, who decided that no formal approval was needed for the cluster-randomised TRIAGE III trial, and that it could be conducted without consent of the patients in accordance with Danish law (Ref.no. FSP-15003590). No further permissions were required for these secondary analyses.
: Not applicable.
: MS and LJHR have received funding for travel from ViroGates A/S, Denmark. JE-O is named as an inventor in patents for the use of suPAR as a prognostic biomarker. The patents are owned by Copenhagen University Hospital, Amager and Hvidovre, Denmark, and are licensed to ViroGates A/S. JE-O is co-founder, shareholder, and CSO of ViroGates A/S. The remaining authors have no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.